IncRNA DGCR5 acts as a tumor suppressor in papillary thyroid carcinoma via sequestering miR-2861

FUKUN CHEN1,2, SHUTING YIN3, JIALUN ZHU1,2, PENGJIE LIU1,2, CHUANZHOU YANG1,2, ZHIPING FENG1,2 and ZHIYONG DENG1,2

1Department of Nuclear Medicine, Yunnan Tumor Hospital; 2Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118; 3Third Ward of The Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China

Received June 8, 2018; Accepted September 13, 2018

DOI: 10.3892/etm.2018.7012

Abstract. A vast amount of evidence indicates that long non-coding RNAs (lncRNAs) are involved in cancer. Previous studies have indicated that IncRNA DiGeorge syndrome critical region gene 5 (DGCR5) is aberrantly expressed in lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma. However, the role of DGCR5 in papillary thyroid carcinoma (PTC) has remained elusive. In the present study, it was revealed that DGCR5 was significantly downregulated in PTC tissues compared with that in adjacent normal tissues. Through functional experiments, it was demonstrated that ectopic overexpression of DGCR5 markedly suppressed PTC cell growth and invasion. A bioinformatics analysis suggested that DGCR5 binds to microRNA (miR)-2861. A total of 5 putative binding sites for miR-2861 were identified in DGCR5, and a luciferase reporter assay confirmed the direct interaction between DGCR5 and miR-2861. Furthermore, reverse transcription-quantitative polymerase chain reaction analysis indicated that ectopic overexpression of DGCR5 led to a decreased expression of miR-2861 in PTC cells and miR-2861 mimic transfection caused a downregulation of DGCR5. miR-2861 level was upregulated in PTC tissues compared with adjacent tissues and negatively correlated with DGCR5 level. In addition, rescue experiments indicated that ectopic expression of miR-2861 reversed the effects of DGCR5 overexpression on PTC cell proliferation and invasion. Taken together, the present results demonstrated that DGCR5 inhibits PTC progression via sponging miR-2861, indicating DGCR5 may serve as a therapeutic target.

Introduction

Thyroid carcinoma (TC) is one of the most prevalent cancer types of the endocrine system and its incidence is gradually increasing (1). According to histologic features, TC may be classified into four types, namely papillary, medullary, follicular and anaplastic TC (2). Among all cases, papillary TC (PTC) accounts for 80% of malignancies (3). Although the outcomes for patients with early-stage PTC are favorable, the five-year survival rate for patients with PTC in the advanced stage remains low (4). Thus, it is crucial to understand the molecular mechanisms of PTC progression and identify more effective therapeutic strategies.

Long non-coding RNAs (lncRNAs) are a group of non-coding RNAs of >200 nucleotides in length (5). lncRNAs have no protein-coding ability and account for a large proportion of genomic transcripts. A vast amount of evidence has indicated that lncRNAs act as modulators in tumor progression (6). lncRNAs have been reported to participate in multiple pathological processes in cancer, including cell survival, proliferation and epithelial-mesenchymal transition (7). Numerous lncRNAs have been observed to be aberrantly expressed in the tissues and to be implicated in the progression of various types of tumor. For instance, IncRNA mucin (MUC)5B-antisense non-coding RNA 1 enhances lung adenocarcinoma metastasis by regulating MUC5B expression (8). Overexpression of IncRNA DQ786243 predicts poor prognosis and contributes to the progression of hepatocellular carcinoma (HCC) (9). Cytoskeleton regulator RNA enhances glioma development via sponging microRNA (miR)-16 (10). These results support the important roles of lncRNAs in cancer.

A previous study revealed that IncRNA DiGeorge syndrome critical region gene 5 (DGCR5) is a suppressor of lung cancer, HCC and pancreatic ductal adenocarcinoma progression (11-13). However, the role of DGCR5 in PTC has remained elusive. The present study therefore aimed to investigate the role of DGCR5 in PTC progression and to determine the underlying mechanisms. It was demonstrated that DGCR5 suppressed PTC cell proliferation and invasion through acting as a sponge for miR-2861. The present study suggested that DGCR5 may be a promising therapeutic target for PTC.
Materials and methods

Patients and samples. A total of 32 PTC samples (14 males and 18 females; age range, 37-61 years old; median age, 52 years old) and adjacent non-cancerous tissues (2 cm away from the lesion) were obtained from Yunnan Tumor Hospital (Kunming, China) between September 2014 and October 2016. All tissues were frozen in liquid nitrogen and stored at -80°C after the surgery. The current study was approved by the Ethics Committee on Human Research of Yunnan Tumor Hospital (Kunming, China). Written informed consent was provided by all patients.

Cell culture. The TPC1 PTC cell line and the Nthyori3-1 human thyroid epithelial cell line were purchased from the Cell Bank of The Chinese Academy of Sciences (Beijing, China) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a humidified atmosphere containing 5% CO2.

Transient transfection. Cells in 6-well dishes were transfected with pcDNA3.1-DGCR5 (2 µg), pcDNA3.1-vector (Addgene, Inc., Cambridge, MA, USA), miR-2861 mimics (50 nM, 5'-GGGGCCUGCCUGGUGGGCGG-3') or negative control mimics (50 nM, 5'-UCACACCCUCUAGAGGAGUAGA-3'; both Shanghai GenePharma Co., Ltd. Shanghai, China) using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocols.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR). RNA isolation from homogenized tissues or cells was performed using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Extracted RNA (1 µg) was reverse-transcribed into complementary DNA using the QuantiTect Reverse Transcription Kit (cat. no. 205313; Qiagen, Valencia, CA, USA). PCR was performed using SYBR-Green Premix Ex Taq II (cat. no. RR820A; Takara, Otsu, Japan) on an Applied Biosystems Step One Plus Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: Initial denaturation at 95°C for 10 min; followed by 40 cycles of denaturation at 95°C for 15 sec and elongation at 60°C for 1 min. Gene expression levels were normalized to the levels of U6 and quantified according to the 2^-ΔΔCq method (14). Primer sequences are listed in Table I. Melting curve analysis was conducted at 95°C for 15 sec, 60°C for 1 min and 95°C for 15 sec for quantification of the results.

Cell Counting Kit (CCK)8 proliferation assay. Cells were seeded into a 96-well plate at 2x10^4 cells/well and cultured for 24, 48 or 72 h. Subsequently, 10 µl CCK-8 stain (Beyotime, Shanghai, China) was added to each well, followed by incubation for 2 h at 37°C and determination of the absorbance at 450 nm using an ELx808 microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).

Transwell assay. For the invasion assay, 2x10^4 cells in 200 µl serum-free medium were placed in each of the upper chambers of a Transwell plate (8 µm pore; Corning, Inc., Corning, NY, USA) whose membrane filters had been pre-coated with Matrigel® (Corning, Inc.). The lower chambers were filled with 600 µl medium containing 10% FBS. After incubation for 24 h, cells on the upper side were wiped away and the cells that had moved into the lower side of the membrane were fixed with methanol for 30 min at 25°C and stained with 0.1% crystal violet for 30 min at 25°C. The cells were observed through an Olympus microscope (Olympus Corp., Tokyo, Japan) and the number of cells was counted in five randomly selected fields. The results were expressed as the average number of invaded cells in each field.

Luciferase assay. The potential targets of DGCR5 were predicted using the miRDB tool (http://mirdb.org/miRDB/index.html). Then DGCR5 sequences containing the wild-type (WT) binding site for miR-2861, the cDNA of which was obtained from the aforementioned RT-qPCR analysis, was amplified by PCR. The mutant (Mut) binding site was synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). These sequences were cloned into pmirGLO vector (Promega Corporation, Madison, WI, USA) to obtain reporter vector. For luciferase reporter assay, miR-2861 or scramble mimics and WT or Mut of DGCR5 fragment were co-transfected into 1x10^4 TPC1 cells along with 2 ng Renilla luciferase herpes simplex virus tyrosine kinase plasmid (Promega Corp., Madison, WI, USA). Luciferase activity was detected using the Dual-Luciferase Reporter Assay System (Promega Corp.) according to the manufacturer’s protocols, and the ratio of Firefly to Renilla luciferase activity was determined.

Statistical analysis. SPSS version 19 (IBM Corp., Armonk, NY, USA) or GraphPad Prism 5.0 (GraphPad Software, Inc, La Jolla, CA, USA) was used for data analysis. All results were expressed as the mean ± standard deviation. Student’s t-test or one-way analysis of variance followed by Tukey’s post-hoc test were utilized to determine the statistical significance of differences between groups. Spearman’s rank correlation analysis was used to determine the correlation between miR-2861 and DGCR5 expression. P<0.05 was considered to indicate a statistically significant difference.

Results

DGCR5 is downregulated in PTC tissues. To identify the potential function of DGCR5 in PTC progression, the levels of DGCR5 were measured in 32 pairs of PTC tissues and adjacent normal tissues by RT-qPCR. The results indicated that DGCR5 was significantly downregulated in PTC tissues compared with that in adjacent normal tissues (Fig. 1A). Similarly, RT-qPCR analysis was used to assess the levels of DGCR5 in the TPC1 PTC cell line and in the Nthyori 3-1 normal thyroid cell line. The results indicated that DGCR5 was also downregulated in the PTC cell line compared with that in the normal cell line (Fig. 1B). These results suggested that DGCR5 may be a tumor suppressor in PTC.

DGCR5 overexpression inhibits PTC cell proliferation and invasion. The present study further sought to explore the roles of DGCR5 in PTC. Thus, DGCR5 was overexpressed in TPC1 cells...
via transfection with pcDNA3.1-DGCR5. RT-qPCR analysis revealed that overexpression of DGCR5 significantly promoted DGCR5 expression compared with that in the control-transfected cells (Fig. 2A). Subsequently, the cells were subjected to CCK8 and Transwell invasion assays to determine the effect of DGCR5 on PTC cell growth and invasion. The results indicated that ectopic expression of DGCR5 markedly inhibited the proliferation and invasion of TPC1 cells (Fig. 2B and C).

**DGCR5 sequesters miR-2861.** To determine the molecular mechanisms of the roles of DGCR5 in PTC, potential target miRs of DGCR5 were predicted by a bioinformatics analysis. Among the miRs identified, miR-2861 stood out, as it had five potential binding sites for DGCR5 (Fig. 3A). Of note, transfection of miR-2861 mimics significantly reduced the levels of DGCR5 in TPC1 cells compared with that in negative control-transfected cells (Fig. 3B). Consistently, overexpression of DGCR5 also led to decreased levels of miR-2861 in TPC1 cells (Fig. 3C), indicating a close association between DGCR5 and miR-2861. To further confirm the direct interaction of DGCR5 and miR-2861, a luciferase reporter assay was performed. The results revealed that ectopic expression of miR-2861 significantly repressed the luciferase activity of DGCR5-WT, but not that of DGCR5-Mut in TPC1 cells (Fig. 3D). These results suggested that DGCR5 sequesters miR-2861 in TPC1 cells.

**Correlation of DGCR5 and miR-2861 levels in PTC.** Next, the levels of miR-2861 in PTC tissues were measured by RT-qPCR. The results illustrated that the miR-2861 levels in PTC tissues were higher than those in normal tissues (Fig. 4A). Furthermore, the levels of DGCR5 were inversely correlated with those of miR-2861 in PTC tissues (Fig. 4B), further supporting that DGCR5 serves as a miR sponge for miR-2861.

**miR-2861 mimics abrogate the effects of DGCR5 overexpression.** The above results demonstrated that DGCR5 regulates miR-2861 levels in PTC cells. Therefore, the present study then sought to determine whether miR-2861 is involved in DGCR5-mediated regulation of PTC cells. A CCK8 and a Transwell invasion assay were performed, and the results indicated that overexpression of DGCR5 inhibited TPC1 cell proliferation and invasion, whereas co-transfection with miR-2861 mimics significantly abrogated this effect (Fig. 5A and B). Taken together, it was demonstrated that DGCR5 acts as a tumor suppressor via sequestering miR-2861.

**Discussion**

Initially, IncRNAs were assumed to represent transcriptional noise with no cellular function. However, it was then demonstrated that IncRNAs possess essential functions in various biological processes, including the regulation of development, the immune response and tumorigenesis (15,16). In cancer, IncRNAs have been proven to affect numerous important cellular processes, including proliferation, apoptosis, invasion and the cell cycle (17).
In lncRNA has been reported to be aberrantly expressed and involved in PTC progression (18). For instance, lncRNA maternally expressed 3 inhibits PTC cell invasion through suppressing Rac family small GTPase 1 (19). lncRNA AB074169 is downregulated and suppresses cell proliferation via modulation of KH-type splicing regulatory protein-mediated p21 expression in PTC (20). lncRNA small nucleolar RNA host gene 12 promotes PTC progression by activating the Wnt/β-catenin axis (21). lncRNA PTC susceptibility candidate 3 contributes to PTC development and progression through inhibiting miR-574-5p (22). lncRNA HIT000218960 promotes PTC cell proliferation by increasing high mobility group AT-hook 2 expression (23). Overexpression of lncRNA NR_036575.1 was reported to promote PTC progression (24).

As for DGCR5, its function has remained to be fully elucidated. Wang et al. (11) reported that DGCR5 promotes non-small cell lung cancer cell stemness by regulating miR-330-5p/CD44 signaling. A study by Chen et al (25) suggested that DGCR5 promotes lung cancer progression.
through sponging miR-1180. In HCC, downregulation of DGCR5 was associated with poor prognosis (13). In addition, Yong et al (12) indicated that DGCR5 is involved in regulating the malignant behavior of pancreatic ductal adenocarcinoma. However, the possible role of DGCR5 and PTC and its progression has remained elusive. To the best of our knowledge, the present study was the first to investigate this issue.

The present study demonstrated that DGCR5 expression was significantly downregulated in 32 PTC tissues compared with that in adjacent normal tissues. A CCK8 and a Transwell invasion assay revealed that ectopic overexpression of DGCR5 significantly suppressed the proliferation and invasion of TPC1 cells. IncRNAs may serve as competing endogenous (ce)RNAs for miRs (26) and previously, DGCR5 was also reported to be a ceRNA in lung cancer (25). Thus, it was further explored whether DGCR5 has a similar mechanism of action in PTC. Through a bioinformatics analysis, miR-2861 was identified as a target of DGCR5. The direct interaction of DGCR5 and miR-2861 was demonstrated by a luciferase reporter assay. miR-2861 overexpression has previously reported to be associated with PTC metastasis (27). Other studies have indicated that miR-2861 is involved in the development of lung and cervical cancer (28,29). The present results indicate that miR-2861 is upregulated in PTC tissues compared with that in adjacent normal tissues, also suggesting that miR-2861 may serve as an oncogene in PTC. Furthermore, rescue experiments demonstrated that miR-2861 overexpression significantly promoted the proliferation and invasion of TPC1 cells transfected with pcDNA3.1-DGCR5.

However, the present study has certain limitations. The mechanism via which DGCR5 expression is regulated in PTC remains elusive. Furthermore, the downstream targets of the DGCR5/miR-2861 axis still require to be elucidated. In addition, it remains to be determined whether DGCR5 regulates any further miRs in PTC. The authors of the current study only used a small number of samples. In the future, more samples were required to determine the association between the expression level of DGCR5 or miR-2861 with tumor clinical features, including tumor stage and metastasis.

Acknowledgements
Not applicable.

Funding
The present study was supported by Yunnan Science and Technology Project [grant no. 2017FE467(-080)].

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
FC, ZF and ZD initiated and designed the work, analyzed and interpreted the results, and wrote this manuscript. SY, JZ, PL
and CY performed some experiments. All authors read and approved the final manuscript.

Ethics approval and consent to participate

For the use of human samples, the protocol for this study was approved by the Institutional Ethics Committee of Yunnan Tumor Hospital and all enrolled patients signed a written informed consent document.

Patient consent for publication

All patients within this study provide consent for the publication of their data.

Competing interests

The authors declare that they have no competing interests.

References